Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
The “risk-on” signal evolved into institutional flood Wednesday as XBI exploded +3.6% closing $126.43 driven by massive secondary offering demand signaling capital strike officially over
The “risk-on” switch flipped 5 days before J.P. Morgan Healthcare Conference as XBI surged +1.6% closing $122.09 with biotech outperforming S&P 500 driven by perfect
The “quiet period” officially ends 6 days before J.P. Morgan Healthcare Conference as Sanofi (SNY) acquires Dynavax (DVAX) for $15.50/share ($2.2B all-cash) securing Heplisav-B hepatitis
The JPM 2026 Planner: Shadow Week Playbook & 5 Stocks to Buy Before Conference Editor’s Note: This post has been updated to reflect corrected data.
CORRECTION: This article has been updated to reflect accurate regulatory outcomes. Original version incorrectly stated Corcept approval and Omeros CRL due to data processing error
Monday validation rally delivered XBI +1.8% breakout to $106.12 confirming market endorsement of weekend’s transformative catalysts as policy clarity (TrumpRx 3-year tariff exemption) outweighs pricing
Senate passes Biosecure Act in NDAA sending to President creating immediate new business ban with Chinese CDMOs (WuXi AppTec, BGI) while grandfathering existing contracts until
Kodiak Sciences defies dilution gravity rallying +11.7% to $26.97 after upsizing $160M Phase 3 retina offering at $23/share signaling institutional conviction in late-stage assets, Immunome
GSK secures FDA approval for Exdensur (depemokimab) as first twice-yearly severe asthma biologic cementing respiratory franchise dominance, Aldeyra crashes -15.5% on March 2026 PDUFA delay
Aldeyra reproxalap PDUFA extended to March 16, 2026 on FDA request for Clinical Study Report triggering -12.1% selloff eliminating Tuesday binary catalyst, Immunome varegacestat hits
